AssureCKD Appoints Former LumiraDx Technical Director Dr. Aman Khan as Chief Technology Officer to Lead Diagnostic Platform Development

This section is Partnership Content suppliedThe content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Article contentVANCOUVER, British Columbia, April 15, 2026 (GLOBE NEWSWIRE) — AssureCKD, a Canadian medical device company developing point-of-care solutions for chronic kidney disease (CKD) screening and diagnosis, today announced the appointment of Dr. Aman Khan as Chief Technology Officer, effective April 13, 2026.Sign In or Create an AccountEmail AddressContinueor View more offersArticle contentDr. Khan brings more than 30 years of experience in diagnostics and medical technology, with a proven track record of leading platform development from concept through to global commercialization. He is also a prolific innovator, with over 50 issued patents across diagnostic technologies and platform architectures.Article contentWe apologize, but this video has failed to load.Try refreshing your browser, ortap here to see other videos from our team.Article contentArticle contentMost recently, Dr. Khan served as Technical Director at LumiraDx, where he led the development of a next-generation point-of-care diagnostic platform and built global, cross-functional teams across the United Kingdom, United States, and Europe. LumiraDx was subsequently acquired by Roche in a transaction valued at approximately $350 million USD.Article contentTop StoriesGet the latest headlines, breaking news and columns.There was an error, please provide a valid email address.Sign UpBy signing up you consent to receive the above newsletter from Postmedia Network Inc.Thanks for signing up!A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againInterested in more newsletters? Browse here.Article contentPrior to LumiraDx, Dr. Khan held senior leadership roles at Alere, a global leader in rapid diagnostics acquired by Abbott Laboratories for approximately $5.8 billion USD. At Alere, he provided technical leadership across multiple diagnostic platforms and integrations, including Biosite and Hemosense.Article contentDr. Khan’s expertise spans R&D strategy, assay development, platform engineering, and regulatory execution. Throughout his career, he has focused on translating complex scientific innovation into scalable, commercially viable diagnostic solutions.Article contentAt AssureCKD, Dr. Khan will lead the company’s technology strategy and execution as it advances its proprietary MATLOC platform toward design lock, validation, and regulatory submission. This appointment comes as AssureCKD accelerates development of its platform, with a focus on advancing assay performance, integrating system components, and preparing for regulatory engagement in the United States.Article contentArticle content“Dr. Khan has played a key role in the development of some of the most successful point-of-care diagnostic platforms in the industry,” said Harrison Ross, Chief Executive Officer of AssureCKD. “His experience scaling technologies from early development through commercialization, combined with his deep expertise in assay development and platform integration, significantly de-risks our path to market as we advance toward key technical and regulatory milestones.”Article content“AssureCKD is addressing a critical gap in the early detection of chronic kidney disease,” said Dr. Khan. “I look forward to working with the team to advance the MATLOC platform and deliver clinically meaningful, scalable diagnostic solutions that can be deployed at the point of care.”Article contentThe appointment comes as AssureCKD prepares for its next phase of growth and financing.Article contentAbout AssureCKDArticle contentAssureCKD is a Canadian medical device company focused on improving the early detection and management of chronic kidney disease. The company is developing a point-of-care diagnostic platform designed to provide rapid, quantitative assessment of key kidney function biomarkers, enabling timely clinical decision-making in decentralized healthcare settings.Article contentForward-Looking StatementsArticle contentThis news release contains forward-looking statements regarding the development and commercialization of AssureCKD’s diagnostic platform. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially.Article contentContact:Article contentinfo@assureckd.comArticle contentArticle contentArticle contentArticle contentArticle contentArticle contentTrending The Great Correction: Not even Wayne Gretzky's hometown could escape the crash of the 'exurbs' Real Estate Trump isolation deepens on world stage as allies rebuff, condemn PMN Business Posthaste: What Mark Carney's gas tax cut could mean for the Bank of Canada News Forcing people to pay a moral tax if they leave the country won't inspire them to stay Personal Finance What is Anthropic's Mythos AI model and why does it have the financial world in a panic? Innovation Share this article in your social networkCommentsYou must be logged in to join the discussion or read more comments.Create an AccountSign in Join the Conversation Postmedia is committed to maintaining a lively but civil forum for discussion. Please keep comments relevant and respectful. Comments may take up to an hour to appear on the site. You will receive an email if there is a reply to your comment, an update to a thread you follow or if a user you follow comments. Visit our Community Guidelines for more information.

The Great Correction: Not even Wayne Gretzky's hometown could escape the crash of the 'exurbs' Real Estate Trump isolation deepens on world stage as allies rebuff, condemn PMN Business Posthaste: What Mark Carney's gas tax cut could mean for the Bank of Canada News Forcing people to pay a moral tax if they leave the country won't inspire them to stay Personal Finance What is Anthropic's Mythos AI model and why does it have the financial world in a panic? Innovation